Trial Profile
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 22 Aug 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jul 2018.